DabigatranDr Ihab Suliman2013
The New Oral Anticoagulants:Similar Yet Different   Thrombin Inhibitors:       1. Dabigatran: pro-drug, renal clearance -...
Dabigatran: FDA StatusPradaxa    trade nameFor the prevention of DVT/PE after orthopedic surgery:  Pradaxa approved in ...
Dabigatran: FDA Approved Dosing150 mg BID for SPAF   150 mg for CrCl >30 mL / min   75 mg for CrCl 15-30 mL / min
Stroke from Atrial FibrillationAF is the most preventable cause of stroke:  12-16 million will be on warfarin treatment ...
Dabigatran: Not Without Issues 1.   No anticoagulant effect if missed dose      • 2% discontinuation rate due to GI distre...
Dabigatran: Laboratory Testing Monitoring vs anticoagulant assessment    PT and aPTT        Differing reagent sensitivi...
Dabigatran guidelines and reversal PPT
Dabigatran guidelines and reversal PPT
Dabigatran guidelines and reversal PPT
Dabigatran guidelines and reversal PPT
Dabigatran guidelines and reversal PPT
Dabigatran guidelines and reversal PPT
Dabigatran guidelines and reversal PPT
Dabigatran guidelines and reversal PPT
Dabigatran guidelines and reversal PPT
Dabigatran guidelines and reversal PPT
Dabigatran guidelines and reversal PPT
Dabigatran guidelines and reversal PPT
Dabigatran guidelines and reversal PPT
Dabigatran guidelines and reversal PPT
Dabigatran guidelines and reversal PPT
Dabigatran guidelines and reversal PPT
Dabigatran guidelines and reversal PPT
Dabigatran guidelines and reversal PPT
Dabigatran guidelines and reversal PPT
Upcoming SlideShare
Loading in …5
×

Dabigatran guidelines and reversal PPT

4,822 views

Published on

Dabigatran 2013 PPT

Published in: Health & Medicine
1 Comment
0 Likes
Statistics
Notes
  • Be the first to like this

No Downloads
Views
Total views
4,822
On SlideShare
0
From Embeds
0
Number of Embeds
5
Actions
Shares
0
Downloads
197
Comments
1
Likes
0
Embeds 0
No embeds

No notes for slide

Dabigatran guidelines and reversal PPT

  1. 1. DabigatranDr Ihab Suliman2013
  2. 2. The New Oral Anticoagulants:Similar Yet Different  Thrombin Inhibitors: 1. Dabigatran: pro-drug, renal clearance - twice daily  FXa Inhibitors: 1. Rivaroxaban: renal clearance - once daily 2. Apixaban: hepatic clearance - twice daily 3. Edoxaban: hepatic clearance - once daily Circulation 2010;121:1523-1532
  3. 3. Dabigatran: FDA StatusPradaxa trade nameFor the prevention of DVT/PE after orthopedic surgery: Pradaxa approved in EU and CanadaFor the prevention of stroke in patients with non-valvular atrial fibrillation (SPAF): Pradaxa 150 mg BID FDA approved (Oct. 2010) Pradaxa approved in EU, Canada and Japan
  4. 4. Dabigatran: FDA Approved Dosing150 mg BID for SPAF  150 mg for CrCl >30 mL / min  75 mg for CrCl 15-30 mL / min
  5. 5. Stroke from Atrial FibrillationAF is the most preventable cause of stroke: 12-16 million will be on warfarin treatment by 2050 in the US Clinical trials have shown stroke can be reduced: Placebo vs ASA = 19% ASA vs warfarin = 30% Placebo vs warfarin = 62% Dabigatran vs warfarin = 34%
  6. 6. Dabigatran: Not Without Issues 1. No anticoagulant effect if missed dose • 2% discontinuation rate due to GI distress • Cost of drug ($240/mo vs $4/mo for warfarin) 2. No test to assess anticoagulation 3. Difficult to modulate dose 4. Bleeding in the elderly and renal impaired patients (5 dabigatran related deaths in Japan) 5. ‘Real world’ untested populations 6. Drug interactions 7. Limited data on bridging between anticoagulants 8. No specific antidote 9. 0.2% increase in myocardial infarction 10. Off-label use
  7. 7. Dabigatran: Laboratory Testing Monitoring vs anticoagulant assessment  PT and aPTT  Differing reagent sensitivities  Not a linear association between assay values and drug level  Not validated for association to bleeding  aPTT may be applicable for qualitative assessment  INR: not sensitive; not validated  TT: Super-sensitive; can identify if any drug onboard  Ecarin clotting time: results can vary depending on plasma factors; research use only (RUO)  PiCT: RUO  Chromogenic anti-FIIa  Hemoclot: quantitative using dabigatran calibrators; FDA approved yet?

×